OBJECTIVE： To investigate the therapeutic effects of aminophylline and ambroterol combined with methylpred- nisolone and terbutaline on bronchial asthma patients. METHODS： A total of 128 hospitalizedy patients with bronchial asthma admitted in Chongqing Jianshe Hospital during Jan.-Jul. 2016 were divided into observation group and control group according to therapy plan， with 64 cases in each group. Control group received Aminophylline tablet and Ambroterol oral solution. Observation group was additionally given intravenous dripping of Methylprednisolone sodium succinate for injection+aerosol inhalation of Terbutaline sulfate solution for nebulization， on the basis of control group. Both groups received treatment for 7 d according to drug package inserts. The duration of cough， shortness of breath， pulmonary rales and wheezing were compared between 2 groups. Lung function indexes （FEV1， PEF） and inflammatory factors （IL-6， IL-10， IL-17） of 2 groups were observed before and after treatment. The occurrence of ADR was also observed. RESULTS： Before treatment， there was no statistical significance in lung function indexes or inflammatory factors between 2 groups （P＞0.05）. Compared with before treatment， the levels of FEV1 and PEF in 2 groups were increased significantly， while the levels of IL-6， IL-10 and IL-17 were decreased significantly， with statistical significance （P＜0.05）. Compared with control group， the duration of cough， shortness of breath， pulmonary rales and wheezing in observation group were shorter； the levels of FEV1 and PEF were higher， while IL-6， IL-10 and IL-17 were lower， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups（P＞0.05）. CONCLUSIONS： Aminophylline and ambroterol combined with methylprednisolone and terbutaline can better alleviate clinical symptoms， and can significantly improve lung function and inflammatory factors.